Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with unresectable stage III non-small cell lung cancer, EGFR exon 19 deletion or exon 21 L858R on an FDA-approved test, and no progression during or after concurrent or sequential platinum chemoradiation.
LAMPGEN ANALYSIS
Why it matters
The LAURA-based indication adds EGFR-directed treatment after definitive chemoradiation for a molecularly selected group.
What research teams should watch
Route molecular results to the radiation team, and document restaging and evaluation of respiratory symptoms before starting.
PRIMARY RECORDS